T-cell engagers
T-cell engagers
Candid and WuXi: $925 Million Cancer Breakthrough!
BIOT
Candid Therapeutics partners with WuXi Biologics to advance trispecific T-cell engagers, aiming for $925 million in potential milestones! 💰🌍📰
Merck Acquiring Harpoon for $680M: Revolutionizing Cancer Treatment!
BIOT
📰 Merck buys Harpoon Therapeutics for $680m, boosting its cancer treatment capabilities. 💊💉 Exciting move in immuno-oncology! 🌟👨🔬🚀
